Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on May 23, 2024. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "LTRN". The report details a corporate governance amendment approved by the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the Company's By-laws and does not contain financial performance data.
Material Changes
On May 23, 2024, the Board of Directors approved an immediate amendment to Section 3.02 of the Company's By-laws regarding the determination of the authorized number of directors. The amendment simplifies the process for fixing the number of directors:
- Previous Provision: The number of directors (between 3 and 9) was fixed by resolution of a majority of the total number of directors that the Corporation would have if there were no vacancies.
- Amended Provision: The number of directors (between 3 and 9) is now fixed by resolution of the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements regarding business operations or financial projections.
Key Facts for Investor Verification
- Verify the effective date of the By-laws amendment (May 23, 2024).
- Confirm the current composition of the Board of Directors to ensure it remains within the 3 to 9 director limit.
- Review the filed Exhibit 3.2 (Amendment No. 1 to Bylaws) for the complete legal text of the change.
- Note that this filing does not impact the Company's financial statements or operational status.